{"id":"asulacrine","rwe":[],"tags":[{"label":"asulacrine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"DNA topoisomerase 2-alpha","category":"target"},{"label":"TOP2A","category":"gene"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:45:01.290910","allNames":"amsalog","offLabel":[],"synonyms":["asulacrine","amsalog"],"timeline":[],"brandName":"Amsalog","ecosystem":[],"mechanism":{"target":"DNA topoisomerase 2-alpha","targets":[{"gene":"TOP2A","source":"DrugCentral","target":"DNA topoisomerase 2-alpha","protein":"DNA topoisomerase 2-alpha"}],"modality":"Small Molecule","drugClass":"asulacrine","explanation":"Imagine your DNA is a long, twisted ladder. DNA topoisomerase 2-alpha is like a special tool that helps untwist the ladder so that the DNA can be copied. Amsalog blocks this tool, which can prevent cancer cells from growing and dividing.","oneSentence":"Amsalog works by blocking the enzyme DNA topoisomerase 2-alpha, which is essential for DNA replication and repair.","technicalDetail":"Amsalog inhibits the catalytic activity of DNA topoisomerase 2-alpha, leading to the accumulation of DNA breaks and ultimately inducing apoptosis in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/252","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=asulacrine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:50:24.006696","biosimilars":[],"competitors":[{"drugName":"daunorubicin","drugSlug":"daunorubicin","fdaApproval":"1979-12-19","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"dexrazoxane","drugSlug":"dexrazoxane","fdaApproval":"1995-05-26","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"doxorubicin","drugSlug":"doxorubicin","fdaApproval":"1974-08-07","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"etoposide","drugSlug":"etoposide","fdaApproval":"1983-11-10","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"etoposide phosphate","drugSlug":"etoposide-phosphate","fdaApproval":"1996-05-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"idarubicin","drugSlug":"idarubicin","fdaApproval":"1990-09-27","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"teniposide","drugSlug":"teniposide","fdaApproval":"1992-07-14","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"valrubicin","drugSlug":"valrubicin","fdaApproval":"1998-09-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"asulacrine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(15)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daunorubicin","brandName":"daunorubicin","genericName":"daunorubicin","approvalYear":"1979","relationship":"same-target"},{"drugId":"dexrazoxane","brandName":"dexrazoxane","genericName":"dexrazoxane","approvalYear":"1995","relationship":"same-target"},{"drugId":"doxorubicin","brandName":"doxorubicin","genericName":"doxorubicin","approvalYear":"1974","relationship":"same-target"},{"drugId":"etoposide","brandName":"etoposide","genericName":"etoposide","approvalYear":"1983","relationship":"same-target"},{"drugId":"etoposide-phosphate","brandName":"etoposide phosphate","genericName":"etoposide phosphate","approvalYear":"1996","relationship":"same-target"},{"drugId":"idarubicin","brandName":"idarubicin","genericName":"idarubicin","approvalYear":"1990","relationship":"same-target"},{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-target"},{"drugId":"teniposide","brandName":"teniposide","genericName":"teniposide","approvalYear":"1992","relationship":"same-target"},{"drugId":"valrubicin","brandName":"valrubicin","genericName":"valrubicin","approvalYear":"1998","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"S8P50T62B6","CHEBI":"CHEBI:135753","UMLSCUI":"C0130561","ChEMBL_ID":"CHEMBL48880","PUBCHEM_CID":"107924","MESH_SUPPLEMENTAL_RECORD_UI":"C042315"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.4 hours","clearance":"2.6 mL/min/kg","bioavailability":"34%","fractionUnbound":"0.0011%","volumeOfDistribution":"0.3 L/kg"},"publicationCount":15,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2020 Apr 10","pmid":"31978442","title":"Size-adaptable and ligand (biotin)-sheddable nanocarriers equipped with avidin scavenging technology for deep tumor penetration and reduced toxicity.","journal":"Journal of controlled release : official journal of the Controlled Release Society"},{"date":"2018 Nov","pmid":"29493300","title":"Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.","journal":"Drug delivery"},{"date":"2018 Jan 4","pmid":"29302821","title":"Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.","journal":"Pharmaceutical research"},{"date":"2016 Aug","pmid":"27321375","title":"Integrated scientific data bases review on asulacrine and associated toxicity.","journal":"Critical reviews in oncology/hematology"},{"date":"2016 Dec","pmid":"27187844","title":"Quantitative determination of intracellular Asulacrine in MCF-7 breast cancer cells by liquid chromatography-mass spectrometry and its application to cellular pharmacokinetic studies of P188 modified liposomes.","journal":"Biomedical chromatography : BMC"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Amsalog is a small molecule. It is also known by other names, including Asulacrine, CI-921, NSC 343499, and SN-21407.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}